Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Michalski

Showing results (271-280 of 331) with videos related to

Pageof 34
Sort By:
Neuro-Oncology|October 29, 2025
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survivalAuthors Kyle S Smith, Sandeep K Dhanda, Catherine A Billups, et al.
Cancer|June 2, 2020
Management of primary skin cancer during a pandemic: Multidisciplinary recommendationsBrian C Baumann, Kelly M MacArthur, Jerry D Brewer, et al.
European Urology|May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 TrialOliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate CancerW Robert Lee, James J Dignam, Mahul B Amin, et al.
European Urology|November 13, 2017
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate CancerStephen J Ramey, Shree Agrawal, Matthew C Abramowitz, et al.
Advances in Radiation Oncology|September 12, 2018
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicitiesCanhua Xiao, Jennifer Moughan, Benjamin Movsas, et al.
International Journal of Radiation Oncology, Biology, Physics|October 18, 2016
Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational StudyThomas M Pisansky, Shree Agrawal, Daniel A Hamstra, et al.
European Urology|June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
International Journal of Radiation Oncology, Biology, Physics|April 10, 2012
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlasHiram A Gay, H Joseph Barthold, Elizabeth O'Meara, et al.
Pageof 34

Showing results (271-280 of 331) with videos related to

Sort By:
Pageof 34
Neuro-Oncology|October 29, 2025
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survivalAuthors Kyle S Smith, Sandeep K Dhanda, Catherine A Billups, et al.
Cancer|June 2, 2020
Management of primary skin cancer during a pandemic: Multidisciplinary recommendationsBrian C Baumann, Kelly M MacArthur, Jerry D Brewer, et al.
European Urology|May 13, 2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 TrialOliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate CancerW Robert Lee, James J Dignam, Mahul B Amin, et al.
European Urology|November 13, 2017
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate CancerStephen J Ramey, Shree Agrawal, Matthew C Abramowitz, et al.
Advances in Radiation Oncology|September 12, 2018
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicitiesCanhua Xiao, Jennifer Moughan, Benjamin Movsas, et al.
International Journal of Radiation Oncology, Biology, Physics|October 18, 2016
Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational StudyThomas M Pisansky, Shree Agrawal, Daniel A Hamstra, et al.
European Urology|June 19, 2024
Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163]Oliver Sartor, Theodore G Karrison, Howard M Sandler, et al.
International Journal of Radiation Oncology, Biology, Physics|April 10, 2012
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlasHiram A Gay, H Joseph Barthold, Elizabeth O'Meara, et al.
Pageof 34